RxDoctor Payments Data

Stefani Seabaugh

Acute Care · Huntsville, ALNPI 1215350004

Payments from drug & device makers

$6,459in general payments, 2019–2025

Across 230 payments — averaging $28.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • E.r. Squibb & Sons, L.L.C.$625
  • Novartis$568
  • Boehringer Ingelheim$480
  • Regeneron Healthcare Solutions, Inc.$464
  • Johnson & Johnson$377
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$85213%
  • Food & beverage$5,60887%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,459 in reported general payments places this provider in the 90th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$69,876
Medicare patients
753
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol99$68,008
EliquisApixaban52$55,523
EntrestoSacubitril/Valsartan74$49,166
JardianceEmpagliflozin46$34,863
Repatha SureclickEvolocumab19$13,608
XareltoRivaroxaban16$13,073
Ranolazine ErRanolazine14$3,115
Valsartan68$2,405
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide26$1,763
Metoprolol Succinate98$1,418
Carvedilol148$1,337
Flecainide Acetate18$992
Spironolactone108$931
Losartan Potassium74$925
Nifedipine ErNifedipine36$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$322$68,00899 claims
PfizerEliquis$266$55,52352 claims
NovartisEntresto$568$49,16674 claims
Boehringer IngelheimJardiance$480$34,86346 claims
Johnson & JohnsonXarelto$377$13,07316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 711 acute care providers in Alabama.

Other acute care in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →